Last updated on July 2020

A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Select Advanced or Metastatic Solid Tumors


Brief description of study

This study is to assess the safety and tolerability, and to assess the preliminary clinical benefit of NKTR-214 when combined with pembrolizumab (KEYTRUDA).

The study is comprised of two groups; dose optimization and dose expansion cohorts.

Dose Optimization will include first-line and second-line melanoma, non-small cell lung cancer (NSCLC), urothelial carcinoma, head and neck squamous cell carcinoma (HNSCC), and hepatocellular carcinoma (HCC) regardless of PD-L1 expression status. This cohort will include patients enrolled in a 3 + 3 dose escalation and intra-patient step-up dose schemas.

The dose expansion cohort will include first-line NSCLC patients regardless of PD-L1 expression status.

Detailed Study Description

NKTR-214 is a cytokine (investigational agent) that is designed to target CD122, a protein which is found on certain immune cells (known as CD8+ T Cells and Natural Killer Cells) to expand these cells to promote their anti-tumor effects. Pembrolizumab is a programmed death receptor -1 (PD-1) blocking, fully humanized, engineered monoclonal antibody of IgG1 isotype that promotes anti-tumor effects.

The study will evaluate the clinical benefit, safety and tolerability of combining NKTR-214 with pembrolizumab and will enroll approximately 100 new patients.

Dose Optimization: will evaluate an every three-week dose regimen (q3w) of NKTR-214 in combination with pembrolizumab in approximately 40 patients given that the optimal dose and dosing schedule of NKTR-214 in combination with pembrolizumab remains unknown. The previously established recommended Phase 2 dose (0.006 mg/kg) of NKTR-214 was studied in combination with nivolumab. Tumors to be studied include first-line and second-line melanoma, non-small cell lung cancer (NSCLC), urothelial carcinoma, head and neck squamous cell carcinoma (HNSCC), and hepatocellular carcinoma (HCC). NKTR-214 will be administered at a starting dose of 0.008 mg/kg q3w. Pembrolizumab will be administered at a dose of 200 mg q3w. Patients will undergo a fixed 3+3 dose escalation followed by intra-patient step-up dose escalation at a dose determined by the safety review committee after reviewing the data in the fixed 3+3 dose escalation.

Dose Expansion: NKTR-214 in combination with pembrolizumab in approximately 58 patients will be evaluated in first-line non-small cell lung cancer (NSCLC). The NKTR-214 dose to be studied is 0.006 mg/kg q3w. This dose is based on the recommended phase 2 dose noted in the monotherapy trial with NKTR-214 (Study 15-214-01, NCT02869295) and an ongoing combination trial (16-214-02, NCT02983045). Pembrolizumab will be administered at a dose of 200mg q3w. Following data review for safety and efficacy, additional patients may be dosed using the findings from the dose optimization cohorts.

Clinical Study Identifier: NCT03138889

Find a site near you

Start Over

Investigator Site - San Francisco

San Francisco, CA United States
  Connect »

Investigator Site - New Orleans

New Orleans, LA United States
  Connect »

Investigator Site -Minneapolis

Minneapolis, MN United States
  Connect »

Investigator Site - Billings

Billings, MT United States
  Connect »

Investigator Site - Las Vegas

Las Vegas, NV United States
  Connect »

Investigator Site - New Brunswick

New Brunswick, NJ United States
  Connect »

Investigator Site - New York

New York, NY United States
  Connect »

Investigator Site - Falls Church

Falls Church, VA United States
  Connect »

Investigator Site - Milwaukee

Milwaukee, WI United States
  Connect »

Investigator Site

Rogers, AR United States
  Connect »

Investigator Site- August

Augusta, GA United States
  Connect »

Investigator Site - Springfield

Springfield, IL United States
  Connect »

Investigator Site - Nashville

Nashville, TN United States
  Connect »

Investigator Site- Augusta

Augusta, GA United States
  Connect »

Investigator Site

Lawrence, KS United States
  Connect »

Investigator Site -Saint Louis Park

Saint Louis Park, MN United States
  Connect »

Investigator Site

Germantown, TN United States
  Connect »

Investigator Site- Fayetteville

Fayetteville, AR United States
  Connect »

Investigator Site - Miami Beach

Miami Beach, FL United States
  Connect »

Investigator Site - Orlando

Orlando, FL United States
  Connect »

Investigator Site - Atlanta

Atlanta, GA United States
  Connect »

Investigator Site- Kansas City

Kansas City, KS United States
  Connect »

Investigator Site - Detroit

Detroit, MI United States
  Connect »

Investigator Site - Saint Louis

Saint Louis, MO United States
  Connect »

Investigator site - Philadelphia

Philadelphia, PA United States
  Connect »

Investigator Site - Houston

Houston, TX United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.